TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

ADARx Pharmaceuticals Announces Positive Interim Phase 1 Clinical Data for its Novel siRNA Targeting Complement Factor B (CFB)

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Adarx Pharmaceuticals
ADARx Pharmaceuticals Announces Positive Interim Phase 1 Clinical Data for its Novel siRNA Targeting Complement Factor B (CFB)

ADARx Pharmaceuticals reported successful Phase 1 clinical trial results for ADX-038, an investigational siRNA therapy targeting complement factor B. A single subcutaneous dose demonstrated near-complete alternative pathway suppression for 6 months, with potential applications in renal, hematologic, and ocular diseases.

Insights
ABBV   neutral

Mentioned as a collaboration partner for siRNA therapeutics development, with no specific performance details provided